
    
      A multi-center, post-treatment follow-up observational study for liver disease subjects with
      or without liver cirrhosis after receiving emricasan or placebo.

      This phase 2 observational study will enroll subjects from Study IDN-6556-07 (Post
      Orthotropic Liver Transplantation - NCT02138253), IDN-6556-12 (NASH Fibrosis - NCT02686762),
      IDN-6556-14 (NASH Cirrhosis and Severe Portal Hypertension - NCT02960204) or IDN-6556-17
      (Decompensated NASH Cirrhosis - NCT03205345) who have received at least one dose of emricasan
      or placebo.
    
  